PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1822386
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1822386
According to Stratistics MRC, the Global Carboxy Therapy Market is accounted for $50.06 million in 2025 and is expected to reach $124.50 million by 2032 growing at a CAGR of 13.9% during the forecast period. Carboxy Therapy is a non-surgical aesthetic procedure where controlled amounts of carbon dioxide gas are injected under the skin. The treatment works by boosting blood circulation, increasing oxygen delivery, and stimulating collagen formation. Commonly applied to minimize cellulite, scars, stretch marks, and stubborn fat, it enhances skin firmness and texture. Through natural tissue repair and rejuvenation, Carboxy Therapy provides an effective, minimally invasive option for skin improvement and body contouring.
According to recent statistics published by the International Society of Aesthetic Plastic Surgery (ISAPS), aesthetic and cosmetic procedures have seen a surge with an overall increase of 19.3% of plastic surgeries performed in 2021.
Increasing demand for non-invasive aesthetic procedures
The growing preference for non-invasive cosmetic treatments is significantly propelling the carboxy therapy market. Consumers are increasingly opting for procedures that offer visible results with minimal downtime and reduced risk. Advancements in device precision and gas delivery systems are enhancing treatment efficacy and patient comfort. The rise of social media and beauty influencers is amplifying awareness and demand for skin rejuvenation and cellulite reduction therapies. Clinics are integrating carboxy therapy into broader anti-aging and body contouring portfolios, supported by digital imaging and personalized treatment planning. As aesthetic medicine shifts toward preventive and maintenance-based care, non-invasive modalities like carboxy therapy are gaining mainstream traction.
Varying regulatory policies and safety concerns
Approval processes differ widely, with some countries enforcing stringent clinical validation and device certification standards. Safety concerns around gas purity, dosage control, and procedural protocols are prompting tighter oversight. Manufacturers must navigate complex compliance landscapes, including CE marking, FDA clearance, and ISO standards. The integration of smart sensors and automated flow regulators is helping address safety gaps but adds to regulatory complexity. Smaller players often face delays and cost burdens, limiting innovation and slowing product rollout in key markets.
Increasing number of aesthetic clinics
Urban centers and tier-2 cities are witnessing a surge in boutique medspas and dermatology chains offering advanced skin treatments. Clinics are investing in compact, multi-functional devices that support carboxy therapy alongside other modalities like microneedling and RF. Emerging markets are embracing franchised models and turnkey solutions, accelerating device adoption. Digital marketing and online booking platforms are expanding patient access and driving procedural volumes. As competition intensifies, clinics are differentiating through technology upgrades, personalized care, and bundled service offerings.
Potential for negative publicity and consumer distrust
Social media amplification of negative experiences may erode consumer confidence and deter new users. Lack of standardized training and certification across providers contributes to procedural variability. Regulatory bodies are increasingly mandating practitioner accreditation and device traceability to mitigate malpractice. Companies are responding with patient education campaigns and transparent safety data to rebuild trust. However, without robust quality assurance and post-treatment support, the market remains vulnerable to skepticism and backlash.
Covid-19 Impact
The pandemic disrupted aesthetic service delivery, with lockdowns halting elective procedures and reducing clinic footfall. Supply chain interruptions affected device availability and maintenance cycles, delaying new installations. However, the crisis accelerated digital engagement, with clinics adopting virtual consultations and remote skin assessments. Demand rebounded post-pandemic as consumers prioritized self-care and appearance enhancement. The shift toward decentralized care and home-use devices is reshaping the delivery model for aesthetic treatments.
The tabletop devices segment is expected to be the largest during the forecast period
The tabletop devices segment is expected to account for the largest market share during the forecast period, due to its versatility and clinical-grade performance. These systems offer precise gas flow control, customizable treatment protocols, and compatibility with multiple applicators. Clinics prefer tabletop units for their durability, ergonomic design, and ability to handle high patient volumes. Integration of touchscreen interfaces and real-time monitoring is enhancing usability and treatment accuracy. Manufacturers are focusing on modular upgrades and software-driven enhancements to extend device lifecycle. As demand for professional-grade equipment rises, tabletop systems remain the backbone of aesthetic infrastructure.
The medspas segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the medspas segment is predicted to witness the highest growth rate, driven by their hybrid model of wellness and cosmetic care. These facilities are rapidly adopting carboxy therapy as part of holistic skin rejuvenation and anti-aging packages. The appeal of non-invasive treatments with minimal recovery time aligns well with medspa clientele. Integration of AI-based skin analysis and personalized treatment plans is boosting procedural uptake. Medspas are leveraging influencer marketing and subscription-based service models to retain customers and scale operations. As consumer demand shifts toward experiential and results-driven care, medspas are emerging as key growth hubs.
During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising disposable incomes and beauty consciousness. Countries like South Korea, China, and India are witnessing rapid expansion of aesthetic clinics and dermatology centers. Government initiatives promoting medical tourism and device localization are fueling market penetration. Regional players are collaborating with global OEMs to introduce cost-effective, culturally tailored solutions. The popularity of skin whitening, anti-aging, and scar reduction treatments is driving carboxy therapy adoption. Technological advancements and aggressive marketing strategies are reinforcing Asia Pacific's leadership in aesthetic innovation.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by strong R&D and early technology adoption. The U.S. and Canada are embracing smart aesthetic devices with integrated analytics and cloud-based treatment tracking. Regulatory bodies are streamlining approval pathways for innovative non-invasive therapies, accelerating commercialization. Clinics are investing in training, certification, and bundled service offerings to enhance patient outcomes. The rise of wellness-focused consumers and demand for personalized skincare is boosting procedural volumes. As digital platforms and influencer ecosystems mature, North America continues to set the pace for aesthetic market evolution.
Key players in the market
Some of the key players profiled in the Carboxy Therapy Market include Fosun Pharmaceutical Co., Ltd., MBE Medical Division, Merz Pharma GmbH & Co. KGaA, Medipark Co., Ltd., Allergan plc, Italcarbo Srl, Alvi Prague, Mezopharma, JONTE, Kastner-Praxisbedarf, Anti-Aging Medical Systems, Carbossiterapia Italiana, DTA Medical, Beijing Jontelaser Technologies Co., Ltd., and Cosmo Pro Ltd.
In July 2025, Neuco UnitedCo., Limited and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced the signing of an exclusive licensing agreement for the manufacturing and commercialization of AR1001 in Greater China, encompassing in Chinese mainland, Hong Kong Special Administrative Region (SAR), Macau SAR.
In April 2024, Merz Therapeutics has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.